1. Concomitant Intra-Aortic Balloon Pump Use in Cardiogenic Shock Requiring Veno-Arterial Extracorporeal Membrane Oxygenation.
- Author
-
Vallabhajosyula S, O'Horo JC, Antharam P, Ananthaneni S, Vallabhajosyula S, Stulak JM, Eleid MF, Dunlay SM, Gersh BJ, Rihal CS, and Barsness GW
- Subjects
- Adult, Aged, Aged, 80 and over, Cardiac Surgical Procedures mortality, Female, Humans, Male, Middle Aged, Myocardial Infarction mortality, Myocardial Infarction physiopathology, Recovery of Function, Risk Assessment, Risk Factors, Shock, Cardiogenic etiology, Shock, Cardiogenic mortality, Shock, Cardiogenic physiopathology, Time Factors, Treatment Outcome, Cardiac Surgical Procedures adverse effects, Extracorporeal Membrane Oxygenation adverse effects, Extracorporeal Membrane Oxygenation mortality, Intra-Aortic Balloon Pumping adverse effects, Intra-Aortic Balloon Pumping mortality, Myocardial Infarction complications, Shock, Cardiogenic therapy
- Abstract
Background: There are contrasting reports on the effectiveness of a concomitant intra-aortic balloon pump (IABP) in cardiogenic shock patients treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO). This study sought to compare short-term mortality in patients with cardiogenic shock treated with VA-ECMO with and without IABP., Methods and Results: We reviewed the published literature from 2000 to 2018 for studies evaluating adult patients requiring VA-ECMO for cardiogenic shock with concomitant IABP. Studies reporting short-term mortality were included. Meta-analysis of the association of IABP with mortality was performed using Mantel-Haenszel models. Subgroup analyses were performed in patients with cardiogenic shock complicating acute myocardial infarction (AMI) and postcardiotomy cardiogenic shock. Twenty-two observational studies with 4653 patients were included. These studies showed high heterogeneity for the total and postcardiotomy cardiogenic shock cohorts and low heterogeneity for the AMI cohort. Short-term mortality was not significantly different in patients with and without IABP 42.1% versus 57.8%; risk ratio, 0.80; 95% CI, 0.52-1.22; P=0.30. However, concomitant IABP with VA-ECMO was associated with lower mortality in patients with AMI (50.8% versus 62.4%; risk ratio, 0.56; 95% CI, 0.46-0.67; P<0.001). There was no difference in mortality in postcardiotomy cardiogenic shock and mixed causes for cardiogenic shock., Conclusions: In cardiogenic shock patients requiring VA-ECMO support, the use of IABP did not influence mortality in the total cohort. In patients with AMI, use of IABP with VA-ECMO was associated with 18.5% lower mortality in comparison to patients on VA-ECMO alone. Further randomized studies are warranted to corroborate these observational data.
- Published
- 2018
- Full Text
- View/download PDF